NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CYCC

Cyclacel Pharmaceuticals Inc

Jun 20 • 04:00PM ET

0.3409

Dollar change +0.0034
Percentage change 1.01	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD BMY VRTX REGN INCY MRK AMGN EXEL PFE NBIX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-48.93	Insider Own	0.00%	Shs Outstand	22.27M	Perf Week	-5.04%
Market Cap	7.59M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	22.27M	Perf Month	-80.52%
Enterprise Value	4.15M	PEG	-	EPS next Q	-	Inst Own	0.46%	Short Float	0.14%	Perf Quarter	-92.89%
Income	-8.35M	P/S	759.00	EPS this Y	-	Inst Trans	-74.60%	Short Ratio	0.02	Perf Half Y	-93.79%
Sales	0.01M	P/B	1.44	EPS next Y	-	ROA	-168.60%	Short Interest	0.03M	Perf YTD	-94.33%
Book/sh	0.24	P/C	2.20	EPS next 5Y	-	ROE	-1949.77%	52W Range	0.25 - 39.84	Perf Year	-98.69%
Cash/sh	0.15	P/FCF	-	EPS past 3/5Y	59.74% 57.31%	ROIC	-271.74%	52W High	-99.14%	Perf 3Y	-99.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	71.43%	52W Low	36.36%	Perf 5Y	-99.97%
Dividend TTM	2.40 (704.02%)	EV/Sales	415.00	EPS Y/Y TTM	86.28%	Oper. Margin	-96235.71%	Volatility	9.85% 23.85%	Perf 10Y	-100.00%
Dividend Ex-Date	Apr 29, 2025	Quick Ratio	5.60	Sales Y/Y TTM	-96.88%	Profit Margin	-59607.14%	RSI (14)	25.12	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.60	EPS Q/Q	99.98%	SMA20	-62.79%	Beta	0.25	Target Price	16.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	-86.53%	Rel Volume	0.92	Prev Close	0.34
Employees	-	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	-95.12%	Avg Volume	1.29M	Price	0.34
IPO	Mar 16, 2004	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,188,714	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$17
Apr-27-20	Resumed	ROTH Capital	Buy	$24
Sep-07-18	Initiated	Ladenburg Thalmann	Buy
Oct-16-15	Initiated	H.C. Wainwright	Buy	$5
Feb-04-10	Initiated	Roth Capital	Buy	$7
Oct-28-09	Initiated	Merriman	Buy
Aug-12-08	Initiated	Piper Jaffray	Buy	$5
Mar-12-08	Reiterated	Needham & Co	Buy	$12 → $7
Mar-12-08	Reiterated	Collins Stewart	Buy	$12 → $13
Mar-12-08	Reiterated	Cantor Fitzgerald	Buy	$10.50 → $9
Nov-27-07	Reiterated	Cantor Fitzgerald	Buy	$14 → $10.50
Aug-10-07	Reiterated	Cantor Fitzgerald	Buy	$12 → $14
Jun-04-07	Reiterated	Needham & Co	Buy	$9 → $12
Apr-23-07	Initiated	Lazard Capital	Buy	$11
Apr-10-07	Initiated	Cantor Fitzgerald	Buy	$12

Show Previous Ratings

Jun-20-25 04:30PM	Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock (GlobeNewswire)
Jun-03-25 04:15PM	CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT (GlobeNewswire) -13.17%
May-15-25 12:50AM	CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE (GlobeNewswire) -5.17%
May-07-25 09:22AM	Cyclacel Pharmaceuticals to implement 1-for-16 reverse stock split; shares fall (Seeking Alpha) -10.14%
09:00AM	CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT (GlobeNewswire)
06:00AM	Loading…
May-06-25 06:00AM	CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE (GlobeNewswire) +18.43%
Apr-02-25 04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire) -8.85% -6.20%
Mar-24-25 07:30AM	Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock (GlobeNewswire)
Feb-27-25 01:38PM	Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership (GlobeNewswire) +14.92%
Jan-03-25 09:01AM	Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar (GlobeNewswire) +24.02%
Dec-05-24 04:05PM	Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs (GlobeNewswire) -7.37%
Nov-14-24 04:15PM	Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds (GlobeNewswire) -12.60%
Nov-13-24 12:22PM	Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds (GlobeNewswire) +9.76%
Nov-12-24 06:00PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss (Zacks) -8.69%
04:45PM	Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
09:15AM	Loading…
Oct-24-24 09:15AM	Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule (GlobeNewswire) -17.86%
Oct-23-24 09:15AM	Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium (GlobeNewswire) -25.87%
Oct-09-24 09:15AM	Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium (GlobeNewswire) -9.78%
Sep-25-24 09:15AM	Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study (GlobeNewswire)
Sep-04-24 09:15AM	Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 09:15AM	Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter (GlobeNewswire)
Sep-02-24 09:55AM	Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-14-24 05:35PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.55% -8.97%
04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 09:15AM	Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 12:00PM	Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-26-24 09:15AM	Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions (GlobeNewswire) +19.53%
Jun-06-24 12:00PM	All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy (Zacks) -6.60%
Jun-04-24 08:00AM	Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting (GlobeNewswire)
Jun-03-24 08:00AM	Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential as a Precision Medicine for Cancer (GlobeNewswire) -19.70%
05:01AM	Loading…
May-15-24 05:01AM	Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) -14.08%
May-14-24 04:05PM	Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire) +11.81%
May-08-24 09:15AM	Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results (GlobeNewswire) +9.95%
May-02-24 04:30PM	Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) -6.04% -19.68%
Apr-30-24 02:37PM	Top Midday Gainers (MT Newswires) +55.88%
07:47AM	Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today? (InvestorPlace)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Apr-01-24 09:15AM	Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer (GlobeNewswire)
Mar-20-24 10:05AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace) -6.37%
04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 04:05PM	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 09:15AM	Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +5.06%
Mar-06-24 09:15AM	Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit (GlobeNewswire) -8.49%
Feb-20-24 09:15AM	Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference (GlobeNewswire)
Jan-30-24 09:15AM	Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-09-24 09:07AM	Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today? (InvestorPlace)
Jan-08-24 09:15AM	Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +28.11%
Jan-02-24 09:15AM	Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 (GlobeNewswire)
Dec-22-23 09:15AM	Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -23.89%
Dec-20-23 10:52AM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2023 (InvestorPlace) -5.34%
10:51AM	CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q3 2023 (InvestorPlace)
Dec-18-23 09:00AM	Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions (GlobeNewswire)
Dec-12-23 04:05PM	Cyclacel Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -10.99%
Nov-30-23 09:15AM	Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC (GlobeNewswire)
Nov-29-23 12:34PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Nov-28-23 05:15PM	Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
Nov-14-23 10:46AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript (Insider Monkey) -35.54%
Nov-13-23 04:05PM	Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 09:15AM	Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results (GlobeNewswire) -7.42%
Aug-10-23 06:42AM	Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.62%
Aug-03-23 09:15AM	Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 12:00PM	Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why (Zacks)
May-16-23 11:42AM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 05:52AM	Q1 2023 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 04:05PM	Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-04-23 09:15AM	Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results (GlobeNewswire) -6.20%
May-03-23 09:15AM	Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit (GlobeNewswire) -11.99%
Mar-08-23 10:45PM	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 09:15AM	Cyclacel Pharmaceuticals to Participate in March Investor Conferences (GlobeNewswire)
06:10AM	Q4 2022 Cyclacel Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-23 04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update (GlobeNewswire)
Feb-27-23 09:15AM	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -8.76%
Jan-30-23 09:15AM	Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference (GlobeNewswire)
Jan-05-23 09:15AM	Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 (GlobeNewswire)
Dec-15-22 09:15AM	Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 (GlobeNewswire)
Nov-09-22 04:05PM	Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 10:33AM	Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release (Zacks) +10.53%
Nov-03-22 09:15AM	Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 09:15AM	Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 (GlobeNewswire) +9.02%
Oct-24-22 09:15AM	Cyclacel Hosting Research & Development Day (GlobeNewswire) +6.67%
Oct-13-22 09:15AM	Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-21-22 09:15AM	Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire) +6.06%
Aug-10-22 04:05PM	Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +26.32%
Aug-03-22 09:15AM	Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-30-22 12:46PM	Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients (Benzinga) -27.03%
09:15AM	Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline (GlobeNewswire)
Jun-22-22 07:04AM	Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors (GlobeNewswire)
Jun-14-22 09:23AM	10 Popular Penny Stocks on Robinhood (Insider Monkey)
May-11-22 04:05PM	Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -11.41% +6.06%
May-04-22 09:15AM	Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results (GlobeNewswire)
Apr-19-22 09:15AM	Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas (GlobeNewswire)
Apr-15-22 08:33AM	We're Keeping An Eye On Cyclacel Pharmaceuticals' (NASDAQ:CYCC) Cash Burn Rate (Simply Wall St.)
Apr-12-22 07:00AM	Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia (GlobeNewswire) -13.60%
Mar-28-22 04:05PM	Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 07:00AM	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-09-22 07:00AM	Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire)
Feb-07-22 07:00AM	Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference (GlobeNewswire)

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lazar David E.	Interim CEO	Feb 26 '25	Sale	0.03	194,628,820	5,507,996	0	Feb 28 04:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYCC

Cyclacel Pharmaceuticals Inc

Upgrade your FINVIZ experience